2154results about How to "High encapsulation efficiency" patented technology

A liposomal aqueous dispersion and method of making the liposomal aqueous dispersion is useful for encapsulation of drugs. The liposomal aqueous dispersion comprises: an aqueous suspension medium; multilamellar liposomes comprising an anionic phospholipid and cholesterol as essential components; neutral phospholipid in a mole ratio of 0 to 40% based on the total amount of said multilamellar liposomes; and a cation moiety-containing water-soluble drug, wherein the electrolyte concentration of said aqueous suspension medium is not more than 40 mM.

The invention discloses a preparation method of essence microcapsules. The preparation method comprises the following steps: (1) dissolving chitosan in acetum; (2) adding emulsifier and essence into the chitosan acetum for high-speed emulsification and dispersion to obtain the chitosan essence emulsion; (3) adding the mixed solution of sodium alginate and sodium tripolyphosphate dropwise into the chitosan essence emulsion; (4) adjusting the pH value of the system to 5-7 with NaOH solution to obtain the condensed essence microcapsules; and (5) adding cross-linking agent into the condensed essence microcapsule system to perform chemical cross-linking process on the condensed essence microcapsules to obtain the essence microcapsules. For the essence microcapsules prepared according to the method disclosed by the invention, as chemical cross-linking process is implemented on the walls of the capsules, the density of the capsule walls and the resistance to the solution alkalinity/acidity are improved, and the application stability of the essence microcapsules is increased; moreover, with small size, the capsules can easily permeate into textile fiber, and the water-washing resistance of the textile fiber is greatly improved.

The invention belongs to the field of pharmaceutical agents, relates to a polymer micelle lyophilized agent encapsulating an insoluble antitumor drug as well as a preparation method and an application thereof. The polymer micelle lyophilized agent is prepared by carrying out molecular self-assembly on a methoxy poly(ethylene glycol) 2000-polyester block copolymer to form micelles, and then encapsulating the insoluble antitumor drug in a hydrophobic core formed by the polyester. The lyophilized agent has high encapsulation rate, high drug loading and small particle size, can significantly improve the water solubility of the insoluble drug and result in passive targeting of more antitumor drugs to concentrate in the tumor tissues, thus improving an anti-tumor treatment effect and reducing the toxic and side effects of drugs, and can be used to prepare the drugs used for the treatment of lung cancer, intestinal cancer, mammary cancer, ovarian cancer, etc. The lyophilized agent can also be quickly dissolved and dispersed to form a transparent micellar solution after water for injection, normal saline solution and the like are added, and is used for the preparation of the drugs for treating primary intestinal cell carcinoma.

The invention discloses nanometer medicament microspheres. The microspheres comprise a medicament, nanoparticles, a polymer and medicinal auxiliary materials. The invention further provides a preparation method of the nanometer medicament microspheres. The method comprises the following steps of: preparing a medicament and medicinal auxiliary materials into a nanometer medicament; adding the nanometer medicament into a polymer-containing organic solvent mixed solution for emulsifying; adding a nanometer medicament-in-oil mixed suspension into a water mixed suspension containing nanoparticles or containing nanoparticles and a surfactant for emulsifying to obtain an oil-in-nanoparticle mixed suspension-nanometer medicament-in-oil compound emulsion; and curing the obtained compound emulsion, and centrifugally collecting microspheres, wherein the obtained microspheres comprise the medicament, nanoparticles, the polymer and the medicinal auxiliary materials. An appropriate polymer material and an appropriate microsphere preparation method are selected, the prepared microspheres have high envelop rate, and a layer of self-assembled nanoparticles on the surfaces of the microspheres has the effects of improving cell adhesion and reducing inflammation and microencapsulation caused by local excessive acid and hydrophobic materials. The method disclosed by the invention can be applied to preparation of other medicament slow release or controlled release microspheres.

The invention provides microparticles for sustained release formulation for physostigmine, pyridostigmine and other therapeutically active carbamates. The microparticles comprise the active compound and a biodegradable polymer such as polyester, poly(phosphate), poly(anhydride), poly(ortho ester), or mixture thereof. In one embodiment, the polymer is poly(d,l-lactide-co-glycolide). The desired release pattern of the active compound may be readily attained by varying the type and amount of the polymer used, including by using a mixture of two polymers, one of which is more hydrophobic. The invention also provides a method of preparing the microparticles and in one embodiment, the microparticles may be prepared by spray drying.

The invention discloses a method for preparing graphene oxide modified composite phase-change microcapsules. The method specifically comprises the following steps: preparing a graphene oxide solid from graphite powder, concentrated sulfuric acid, sodium nitrate, potassium permanganate and deionized water; mixing the obtained graphene oxide solid with absolute ethyl alcohol and a silane coupling agent, and performing a reaction so as to obtain a double-bond modified functional graphene oxide solid; uniformly mixing the obtained functional graphene oxide solid with a phase-change material, a reaction monomer, a cross-linking agent, a reactive emulsifier and deionized water, and performing ultrasonic dispersion so as to form an oil-in-water type pre-emulsion; and putting the obtained oil-in-water type pre-emulsion into a hot water bath, continuously stirring, further adding an initiator solution, and performing a heat-preservation reaction, thereby obtaining the graphene oxide modified composite phase-change microcapsules. By adopting the method disclosed by the invention, composite phase-change microcapsules which are high in encapsulation efficiency, stable in property, good in heat conductivity, appropriate in phase-change temperature and relatively high in phase-change latent heat enthalpy can be prepared.

The invention discloses slow-release microspheres coated with rivastigmine tartrate/rivastigmine for PLGA/PLA injection and a preparation method thereof. The slow-release microspheres mainly comprise rivastigmine tartrate/rivastigmine and PLGA and PLA serving as biodegradable polymer medicinal materials, and can be prepared by adopting a W1/O/W2 composite emulsified solvent volatilization method, an O/W emulsified solvent volatilization method, an O1/O2 emulsion drying method and a spray drying method. The grain diameter of the microspheres is less than 100 microns. The slow-release microspheres have high medicament loading amount, have no obvious burst release effect, can be continuously released for one week, one mouth or three mouths, are used for treating senile diseases such as Alzheimer's disease, Parkinson disease and the like, and can prolong the acting time of the medicament, reduce the application times and greatly improve the administration compliance of patients.

The invention relates to the field of medicine preparation, in particular to a melittin lipidosome preparation. The lipidosome preparation is composed of one part of melittin, 5-40 parts of phospholipid, 1.3-10 parts of cholesterin and 10-140 parts of poloxamer. The invention also discloses the preparing method of the melittin lipidosome preparation. The melittin lipidosome preparation not only can delay the medicine release in the lipidosome, prong the circulating time in the blood and improve the bioavailability of the medicine, but also can obviously reduce the side effect of the medicine and improve the adaptability of a patient.

The invention relates to a multi-vesicular liposome, a blank multi-vesicular liposome and a preparation method and application thereof. The multi-vesicular liposome contains the following components in part by weight: 1 part of liposome, 0.01 to 20 parts of auxiliary emulsifier, 1 to 50 parts of osmotic pressure regulator and medicinal active ingredients; the medicament-to-lipid ratio of the multi-vesicular liposome is 1:(0.1-1):200; the lipid contains of a specific amount of neutral phospholipid, cholesterol and triglyceride; and the auxiliary emulsifier is selected from dextran, polyvinyl pyrrolidone, hydroxyethyl starch, gelatin, albumin, arginine and hydroxymethyl starch. The blank multi-vesicular liposome contains the following components in part by weight: 1 part of lipid, 0.01 to 20 parts of auxiliary emulsifier, 1 to 50 parts of osmotic pressure regulator and 0.1 to 50 parts of ion gradient regulator; the osmotic pressure of the in vivo water phase of the multi-vesicular liposome is equal to the osmotic pressure of human plasma; and the auxiliary emulsifier is as previously mentioned. The multi-vesicular liposome has high entrapment rate, and can achieve good sustained-release effect on in vivo and in vitro experiments.

A chitosen-quaternary ammonium salt nanoparticle as the carrier of protein-type medicine is prepared through dissolving chitosan-quaternary ammonium salt in distilled water, stirring while adding solution of sodium tripolyphosphate, cross-linking, centrifugal separation, and freeze drying. It has long relesing period (6 days).

Polymeric nanoparticles encapsulating inhibitory ribonucleic acids (RNAs) and methods of their manufacture and use are provided. Advantageous properties of the nanoparticles include: 1) high encapsulation efficiency of inhibitory RNAs into the nanoparticles, 2) small size of the nanoparticles that increases cell internalization, and 3) sustained release of encapsulated inhibitory RNAs by the nanoparticles that allows for administration of an effective amount of inhibitory RNAs to cells or tissues over extended periods of time. Encapsulation efficiency of inhibitory RNAs into the nanoparticles is greatly increased by complexing the inhibitory RNAs to polycations prior to encapsulation. Methods of using the polymeric nanoparticles for treating or inhibiting diseases or disorders are provided.

The invention belongs to the field of medicine preparation and particularly relates to a docetaxel solid lipid nanoparticle and a preparation method thereof. The docetaxel solid lipid nanoparticle consists of an effective curative dose of docetaxel, solid lipid materials, liquid lipid materials, an emulsifying agent, additives, long-circulating auxiliary materials and water for injection. The docetaxel solid lipid nanoparticle provided by the invention has the characteristics of stable docetaxel structure, phagocytosis prevention of an in-vivo reticuloendothelial system and active tumor targeting, and can be stably stored.

The invention discloses a method for preparing a lignin urea-formaldehyde pesticide microcapsule. According to the invention, the method comprises the following steps: taking modified lignin, formaldehyde and urea as a monomer, forming a water-soluble performed polymer under base catalysis, diluting and forming continuous phase, forming dispersed phase by pesticide, an organic solvent and a surfactant, mixing and stirring the continuous phase and the dispersed phase to form an oil-in-water emulsion, performing in situ condensation polymerization under the acidic condition, heating and solidifying, pumping filtration and washing, drying to obtain the solid microcapsule particles. The modified lignin is obtained by formaldehyde hydroxymethyl modification of the industrial grade wheat straw soda lignin. According to the invention, the waste wheat straw soda lignin in paper industry is taken as the main wall material, so that the production cost of the microcapsule can be effectively reduced and the resource utilization of waste biomass can be realized. The preparation method of the invention has the advantages of simple process, rapidity and controllable microcapsule particle size, and is capable of realizing the industrial production, increasing the pesticide utilization rate, prolonging the persistent period, minimizing the environmental pollution in the process of agriculturalproduction, reducing the agriculture production cost and the like, and has good market prospect.

A new formulation of dehydrated lipid vesicles employs a vesicle preserver and permits the control of release and delivery of active pharmaceutical ingredients into the respiratory system for treatment in particular of asthma. The typical formulation provides controlled release of the active pharmaceutical ingredient from 0% to 100% from 0 to 72 hours after inhalation, changes the systemic administration to topical administration, allows prolonged therapeutic period for one administration, increased stability, with reduced dose, reduced systemic side effects, reduced toxicity.

The invention relates to flexible nanoliposomes with charges for cosmetics and a preparation method thereof. The flexible nanoliposomes with the charges for the cosmetics comprise the following components in part by weight: 1-1000 parts of neutral phospholipid, 0.5-500 parts of phospholipid with the charges, 1-1000 parts of cholesterol, 0.5-500 parts of surface active agent, 0.1-20 parts of hyaluronic acid, 0.5-250 parts of cosmetic active ingredients and 100-8000 parts of freeze drying protective agent. The flexible nanoliposomes with the charges for the cosmetics can obviously improve the stabilities of the cosmetic active ingredients, promote the percutaneous absorption and the interaction efficiency of the active ingredients, and also improve the retention and action time of the active ingredients on the skin surface and the skin deep layer; and the flexible nanoliposomes with the charges for the powdery cosmetic active ingredients are also benefit to the use, transportation and storage. The preparation method of the flexible nanoliposomes with the charges can adopt a mechanized method, so the stability of the product technology and quality is good, and the repeatability is high.

The invention relates to a preparation and application of a new macromolecule lipidosome. The structure is a vesicle which has a lipide dual-layer structure containing duoparental chitosan longchain alkyl quaternary ammonium salt as well as phospholipid with micromolecule. The chitosan longchain alkyl quaternary ammonium salt is characterized in that: the weight average molar mass is bigger than 2000; the chitosan longchain alkyl quaternary ammonium salt can be dissolved in chloroform and other organic solvent, which contains carboxyl, amino or quaternary ammonium salt radical and concretely is one of the duoparental chitosan longchain alkyl quaternary ammonium salt disclosed by 200710056993.4 of China Invention Patent. The surface of the macromolecule lipidosome can be connected with various Liver-Targeted preparations. The macromolecule lipidosome can carry water-soluble, oil-dissolving or duoparental materials including medicine, protein, gene, nutrition, vitamin, magnetic granule and quantum dot, etc. The macromolecule lipidosome has the advantages of high wrapping rate, simple and convenient operation, strong applicability and low cost; the macromolecule lipidosome after being covered has even distributed granule diameter which can be lower than 20nm for the smallest, has stable system and strong functions for carrying medical tiny balls and slowly controlling as well as releasing.

The invention provides a temperature-sensitive amphiphilic cyclodextrin polymer PCEC (polycaprolactone-polyethylene glycol-polycaprolactone, PCL-PEG-PCL). The polymer provided by the invention is the amphiphilic cyclodextrin polymer which is obtained by linking a PCL-PEG-PCL molecule with beta-CD (cyclodextrin) through utilizing the temperature-sensitive characteristic of a PCL-PEG-PCL triblock copolymer and the inclusion effect of beta-CD on a hydrophobic medicament, can effectively load and slowly release a hydrophobic or water-soluble medicament on the basis of the traditional hydrogel encapsulated water-soluble medicament, has proper critical gel temperature and can form in situ temperature-sensitive hydrogel after injection. According to the invention, the hydrophobic zone of the polymer is obviously enlarged, thereby effectively improving the loading capacity of the hydrogel on the hydrophobic medicament and obtaining high medicament encapsulation rate and medicament loading amount; and simultaneously, the controlled-release effect of the medicament after local injection delivery is realized by utilizing the temperature-sensitive gel performance of the polymer. The polymer provided by the invention has the following chemical structure shown in the specification.

The present invention relates to nanoparticles for encapsulating compounds, the preparation and uses thereof, said nanoparticles being based on half (C₁-C₄) alkyl esters of poly (methyl vinyl ether-co-maleic anhydride) (PVM/MA) copolymers. Said nanoparticles can encapsulate or incorporate a product of interest for use in the agricultural, cosmetic, food or pharmaceutical fields.

The present disclosure relates to processes for preparing microparticles using an emulsion process where both a solvent and a salt are used in the continuous phase of the emulsion. The present disclosure also relates to micropartices having an angle of repose of ≦35, as measured using a Hele-Shaw cell.

A method for implementing Identity and Locator Split is provided. The method is applied in a MPLS network. ITR and ETR are also LERs in the MPLS network. The method includes: establishing a point to point LSP tunnel between ITR and ETR by running a MPLS signaling protocol; the ITR storing an EID of endpoint and RLOC mapping as well as a RLOC and outer MPLS label mapping, and forwarding the endpoint's data packets in the MPLS network based on the outer MPLS label corresponding to the RLOC. A data encapsulation method for Identity and Locator Split and a LER device in the Identity and Locator Split network are also provided in the present invention. The present invention greatly improves the encapsulation and transmission efficiency of LISP data packets in the MPLS network.